Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)

This study aims to determine the positive predictive value of incidental cardiac uptake on bone scintigraphy for diagnosing transthyretin cardiac amyloidosis, in patients who underwent scintigraphy for reasons other than suspected amyloidosis. The study is an observational, descriptive, multicenter, national study using retrospective data from routine care. Patients with incidental cardiac uptake will be recalled for further diagnostic assessment.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Cardiac Amyloidosis Amyloid Neuropathies Amyloid Neuropathies, Familial Amyloidosis Amyloidosis, Familial Amyloidosis, Hereditary, Transthyretin-Related Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System Metabolic Diseases Metabolism, Inborn Errors Nervous System Diseases Neurodegenerative Diseases Neuromuscular Diseases Nutritional and Metabolic Diseases Peripheral Nervous System Diseases Proteostasis Deficiencies Transthyretin Amyloidosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adults (≥ 18 years)
Patients who underwent bone scintigraphy with 99mTc-HMDP/DPD/PYP for any indication
Incidental cardiac uptake (Perugini grade ≥2) confirmed by a nuclear medicine specialist

Exclusion criteria

Patients under legal protection
Patients refusing the reuse of their data after individual information

Treatment and study plan

Primary outcomes

Cardiac amyloidosis diagnosis

Time frame: After the reassessment evaluation (one-day evaluation)

Study contacts

Contact information is provided by the study sponsor or research team.

Marc-Antoine DELBARRE

CONTACT

[email protected]

+33 3 20 44 59 69

Sponsors and collaborators

Lead sponsor

University Hospital, Lille

Other

Collaborators

Pfizer

Registry information

Official study title

Retrospective Identification of Scintigraphic Cardiac Amyloidosis Using Deep Learning-based Model

Acronym: RISCA

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Apr 10, 2025
Registry last updated: May 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Enrolling by Invitation